Literature DB >> 30242087

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

Prithviraj Bose1, Aziz Nazha2, Rami S Komrokji3, Keyur P Patel4, Sherry A Pierce1, Najla Al-Ali3, Andrew Sochacki5, Aaron Shaver6, Wencai Ma7, Xiaoping Su7, Naval G Daver1, Courtney D DiNardo1, Guillermo Garcia-Manero1, Sanam Loghavi4, Carlos Bueso-Ramos4, Hagop M Kantarjian1, Mikkael A Sekeres2, Michael R Savona5, Jaroslaw P Maciejewski8, Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30242087      PMCID： PMC6236463          DOI： 10.1182/blood-2018-05-848473

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  24 in total

1.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.

Authors:  Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

2.  SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Authors:  F Damm; R Itzykson; O Kosmider; N Droin; A Renneville; V Chesnais; V Gelsi-Boyer; S de Botton; N Vey; C Preudhomme; A Clavert; E Delabesse; S Park; D Birnbaum; M Fontenay; O A Bernard; E Solary
Journal:  Leukemia       Date:  2013-02-05       Impact factor: 11.528

3.  Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience.

Authors:  Aref Al-Kali; Ahmed Kamel Abou Hussein; Mrinal Patnaik; Darci Zblewski; Naseema Gangat; Shahrukh Hashmi; Michelle Elliott; William Hogan; Mark Litzow
Journal:  Leuk Lymphoma       Date:  2018-02-21

4.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

5.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

6.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

Review 7.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

8.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

9.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
View more
  14 in total

1.  Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Authors:  Laura Palomo; Manja Meggendorfer; Stephan Hutter; Sven Twardziok; Vera Ademà; Irene Fuhrmann; Francisco Fuster-Tormo; Blanca Xicoy; Lurdes Zamora; Pamela Acha; Cassandra M Kerr; Wolfgang Kern; Jaroslaw P Maciejewski; Francesc Solé; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2020-10-15       Impact factor: 22.113

Review 2.  Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Mrinal M Patnaik; Terra L Lasho
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 3.  Canonical Wnt: a safeguard and threat for erythropoiesis.

Authors:  Rosa A Krimpenfort; Micha Nethe
Journal:  Blood Adv       Date:  2021-09-28

4.  MDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene.

Authors:  Peter Molony; Adam C Smith; Shamini Selvarajah; Ali Sakhdari
Journal:  Cytogenet Genome Res       Date:  2022-01-17       Impact factor: 1.636

5.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

Review 6.  Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Authors:  Laura Palomo; Pamela Acha; Francesc Solé
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

7.  Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Theodoros Karantanos; Lukasz P Gondek; Ravi Varadhan; Alison R Moliterno; Amy E DeZern; Richard J Jones; Tania Jain
Journal:  Br J Haematol       Date:  2021-05-24       Impact factor: 8.615

Review 8.  Neoantigens in Hematologic Malignancies.

Authors:  Melinda A Biernacki; Marie Bleakley
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

Review 9.  Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology.

Authors:  Theodoros Karantanos; Tania Jain; Alison R Moliterno; Richard J Jones; Amy E DeZern
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

10.  Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.

Authors:  Qian Wang; Hai-Ping Dai; Dan-Dan Liu; Jun-Dan Xie; Hong Yao; Zi-Xuan Ding; Ting-Ting Tao; Su-Ning Chen; Ri Zhang
Journal:  Leuk Res Rep       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.